Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CicloMulsion
- Development stage
- Discontinued
- Lead developer
- Hospices Civils de Lyon
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CicloMulsion is a Cremophor-free, lipid emulsion formulation of the small molecule cyclosporine A, originally developed by NeuroVive Pharmaceutical (now Abliva). In the context of the CLOTILDE trial led by Hospices Civils de Lyon, it was investigated for its potential to reduce myocardial reperfusion injury in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock. Unlike its traditional role as an immunosuppressant (which involves calcineurin inhibition), its cardioprotective mechanism focuses on binding to cyclophilin D (peptidyl-prolyl cis-trans isomerase F) within the mitochondria. This binding inhibits the opening of the mitochondrial permeability transition pore (mPTP), a critical event in cell death during reperfusion. The formulation is designed for intravenous bolus administration during the reperfusion phase of treatment. The CLOTILDE trial was ultimately terminated following negative results from the larger CIRCUS trial evaluating cyclosporine in STEMI patients.
- Brand names
- CicloMulsion
- Other names
- cyclosporinecyclosporine ACsAciclosporin
02
Targets
MPTP (Mitochondrial permeability transition pore)PPIF (Cyclophilin D)
Beyond the preview
Go deeper on CicloMulsion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CicloMulsion.